Resistant Hypertension in a Dialysis Patient by Gallacher, Peter et al.
 
 
 
 
 
Edinburgh Research Explorer 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Resistant Hypertension in a Dialysis Patient
Citation for published version:
Gallacher, P, Farrah, T, Dominiczak, AF, Touyz, RM, Adamczak, M, Barigou, M, Zoghby, Z, Hiremath, S &
Dhaun, N 2020, 'Resistant Hypertension in a Dialysis Patient', Hypertension.
https://doi.org/10.1161/HYPERTENSIONAHA.120.15022
Digital Object Identifier (DOI):
10.1161/HYPERTENSIONAHA.120.15022
Link:
Link to publication record in Edinburgh Research Explorer
Document Version:
Peer reviewed version
Published In:
Hypertension
Publisher Rights Statement:
this is accepted authors manuscript
General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s)
and / or other copyright owners and it is a condition of accessing these publications that users recognise and
abide by the legal requirements associated with these rights.
Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer
content complies with UK legislation. If you believe that the public display of this file breaches copyright please
contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and
investigate your claim.
Download date: 04. Jan. 2021
   
 
 1 
Resistant Hypertension in a Dialysis Patient  
 
Peter J. Gallacher1, Tariq E. Farrah1, Anna F. Dominiczak2, Rhian M Touyz3, Marcin Adamczak 4, 
Mohammed Barigou 5, Ziad Zoghby 6, Swapnil Hiremath7, Neeraj Dhaun1,   
 
Resistant Hypertension in a Dialysis Patient 
 
1 Department of Renal Medicine, Royal Infirmary of Edinburgh, 51 Little France Crescent, Edinburgh, 
EH16 4SA & University/British Heart Foundation Centre of Research Excellence, Centre of 
Cardiovascular Science, University of Edinburgh, Queen's Medical Research Institute, 47 Little France 
Crescent, Edinburgh, EH16 4TJ 
 
2 Institute of Cardiovascular and Medical Sciences, College of Medical, Veterinary and Life Sciences, 
University of Glasgow, UK 
 
3 Institute of Cardiovascular and Medical Sciences, BHF Glasgow Cardiovascular Research Centre, 
University of Glasgow, Glasgow, United Kingdom 
 
4 Department of Nephrology, Transplantation and Internal Medicine, Medical University of Silesia, 
Katowice, Poland 
 
5 Endocrinology Diabetes and metabolism division, Centre hospitalier universitaire Vaudois (CHUV), 
Avenue de la Sallaz 8, 1011, Lausanne, Switzerland 
 
6 Division of Nephrology and Hypertension, Department of Medicine, Mayo Clinic College of Medicine, 
Rochester, MN, United States 
 
7 Division of Nephrology, Department of Medicine, University of Ottawa, Ottawa, Canada 
 
 
For Correspondence:  Dr Neeraj Dhaun (Bean) 
       The Queen’s Medical Research Institute 
47 Little France Crescent, Edinburgh.   
EH16 4TJ  
Telephone:   +44 131 242 9100  
E-mail:   bean.dhaun@ed.ac.uk  
 
 
 
The following case was presented on 23 June 2019 as part of the Clinical-Pathological conference 
chaired by Anna F. Dominiczak and Rhian M Touyz at the European Meeting on Hypertension and 
Cardiovascular Protection in Milan, Italy. Peter Gallacher and Neeraj Dhaun presented the case. 
 
 
 
   
 
 2 
 
Case Introduction 
We present a case of resistant hypertension in a patient with chronic kidney disease (CKD). The 
patient is a 41-year-old woman who first presented to her general practitioner (GP), almost 20 years 
ago, with peripheral edema and lethargy. She is a lifelong smoker and is obese. Her past medical 
history includes asthma and cervical spondylosis. The reason for referral to the renal team was 
dipstick-positive proteinuria in the context of low-serum albumin. 
As this case is from Scotland, the majority of results will be reported in SI units. In the context of a 24-
hour urinary protein excretion of almost 4 grams per 24 hours, hypoalbuminemia of 25 grams per liter, 
and clinical evidence of peripheral edema bilaterally to her knees, a diagnosis of nephrotic syndrome 
was made. The patient’s renal function and blood pressure (BP) were normal at this stage. 
Some of her initial blood results are shown in Table 1. She was not anemic and had normal white cell 
count and inflammatory markers. However, her serum cholesterol and triglycerides were markedly 
elevated. An immunology screen was negative, as was blood-borne virus serology. 
Pictures of the patient's renal biopsy, from which she was diagnosed with primary membranous 
nephropathy are shown in Figure 1. On the left there is evidence of glomerular basement thickening; 
on the right, there is evidence of granular IgG deposition, which is typical for this disease. 
Membranous nephropathy is a cause of nephrotic syndrome in adults, and over four-fifths of cases are 
associated with increased levels of phospholipase A2 receptor antibodies. Hypertension is present in 
up to half of patients with membranous nephropathy at the time of diagnosis. 
At the time of presentation, 20 years ago, management of membranous nephropathy largely revolved 
around the treatment of BP and proteinuria. In keeping with this, the patient was commenced on an 
angiotensin-converting enzyme (ACE) inhibitor and loop diuretic. 
The patient's BP readings over the first 12 months are shown in Figure 2A.  
The patient's BP increased over the first six months after diagnosis, despite a doubling in doses of 
both the ACE inhibitor and loop diuretic. Although no longer routinely practiced in the United Kingdom, 
the patient also received an angiotensin receptor blocker (ARB) at four months to provide dual 
blockade of the renin-angiotensin system (RAS). The patient's excretory function remained within the 
reference range for the first six months (Figure 2B). Despite this treatment, the patient remained 
heavily proteinuric and hypoalbuminemic (Figures 2C and D). 
In summary, the patient had clinical features of ongoing nephrotic syndrome, with  increasing clinic BP 
readings. For discussion, is there any additional information you would like to know at this stage? 
What are the key factors driving this patient's hypertension? Are there any suggestions for ways in 
which we can manage this patient's BP at this stage? 
 
Discussion 
Prof. Dominiczak: Why would you combine ACE inhibitor and ARB? All guidelines say no, in red, in very 
big letters. 
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Dr. Dhaun: That is an excellent question, thank you. This case is from around 20 years ago and it was 
managed by nephrology. At that time, most management of nephrotic syndrome was targeted at 
reducing proteinuria. The drugs with the best evidence to do this in CKD are ACE inhibitors or ARBs. 
Either drug alone will reduce proteinuria by around 30-50%. The effect of adding in the second agent is 
to give an additional reduction in proteinuria of around 10-20%. This is due to additive blocking of the 
RAS, with combination treatment giving up to about 90% RAS blockade. In current times, we would try 
and avoid dual RAS blockade.  
What other information would you like? We have a lady in her early 40s with nephrotic syndrome. 
Dr. Nademi: I'm Dr. Nademi from Iran, intervention cardiologist. I want to know about kidney imaging 
data: sonographies, CT, angiography. 
Dr. Dhaun: Thank you for your question. As this lady underwent a kidney biopsy, she had an ultrasound 
scan of the kidneys at the same time. This was unremarkable. 
Dr. Nademi: What about renal arteries? Was there any evaluation, including scan or angiography? 
Dr. Dhaun: We did perform doppler ultrasonography and this demonstrated no compromise of renal 
blood flow. At that time, we did not proceed to a CT scan or formal angiography. 
Dr. Adamczak: I've got one remark. Do you use furosemide? The patient has normal kidney function at 
this stage of CKD. 
Dr. Dhaun: Yes, the patient was already prescribed a loop diuretic. 
Dr. Adamczak: Taking into account anti-hypertensive properties, first of all, you should use a thiazide 
or thiazide-like diuretic. The antihypertensive properties of these agents are more potent than loop 
diuretics. Therefore, if the patient has good kidney function, you should start with the thiazide or 
thiazide-like diuretic. Second question, what is the treatment of underlying diseases? Were steroids, 
cyclosporine A, or tacrolimus used, or were you just waiting? 
Dr. Dhaun: In response to your first question about the choice of antihypertensive, this patient had 
nephrotic syndrome, and, in the renal community, we would probably choose an RAS blocker first-line, 
probably an ACE inhibitor. In terms of managing fluid overload alongside this in context of nephrotic 
syndrome, we would probably choose a loop diuretic first. We may then add in a thiazide diuretic. In 
response to your question about the treatment of underlying membranous nephropathy, this case is 
from 20 years ago and, at that time, perhaps even now, standard of care is conservative management, 
that is, BP and proteinuria control, for six months. In this case, we are still within that 6-month window. 
Dr. Mallamaci: First, I'd like to have a 24-hour profile of the patient, then maybe a calcium channel 
blocker. 
Dr. Dhaun: I think those are excellent suggestions.  
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Prof. Touyz: It was interesting that, as you added more drugs, the BP went up. I'm going to ask you 
about the doses of the drugs you used, particularly with respect to candesartan and patients with 
proteinuria. Around 10-12 years ago, there was the notion that doses that were being used were 
suboptimal. In fact in 2009, a study by Ellen Burgess and her colleagues in Calgary showed that 
supramaximal doses of candesartan had some benefit in patients with hypertension and proteinuric 
kidney disease. I'd be curious to know if you would have considered that at this point? 
Dr. Dhaun: Indeed, supra-therapeutic doses of ARB were in vogue at that time. In the U.K., the 
maximum licensed dose of candesartan is 32 mg daily. In this patient we went as high as 64 mg daily. 
There was some data at that time suggesting that doses as high as 128 mg might be beneficial for 
maximum proteinuria reduction. There may be worries about combining an ACE and an ARB in patients 
with CKD, especially in those with nephrotic syndrome, which is characterized by a state of 
intravascular volume depletion. With dual RAS blockade in this context, a renal ‘hit’, such as diarrhea or 
vomiting, may precipitate acute kidney injury. 
Dr. M. Barigou: We didn't discuss the risk factors contributing to hypertension in this case. This patient 
is obese, and she has a renal disease with a massive proteinuria, which are three major risk factors 
contributing to her hypertension. To improve her blood pressure, we should appropriately treat every 
one of these identified risk factors. Moreover, concerning hypertension management, we have data 
comparing sequential RAAS blockade versus nephron blockade in CKD patients, and we know that the 
latter is probably more efficient by inducing a large and well-tolerated reduction in blood pressure via a 
progressive increase in sodium depletion (ref: Bobrie G, Frank M, Azizi M, et al. J Hypertens. 
2012;30(8):1656–1664). 
Dr. Dhaun: These are all important points that we will cover as the patient’s journey continues. 
Prof. Touyz: Perhaps we'll address the case, and then we can bring up more discussion in a little while. 
 
Case Progression 
Twenty-four-hour BP monitoring was performed and confirmed that the patient did indeed have 
sustained hypertension throughout the 24-hour period, without the expected 10% dip in overnight 
readings (Table 1). The patient's 24-hour urinary sodium excretion also suggested that her dietary salt 
intake was very high. 
 Both electrocardiogram (ECG) and echocardiogram were normal at this stage, and there were no 
abnormalities on fundoscopy. Serum and urinary cortisol were also normal, as were urinary 
metabolites. Broadly, general factors contributing to this patient's hypertension include underlying 
essential hypertension and her adherence to medications (Table 2). Lifestyle, as has been pointed 
out, is also very relevant, especially given we are from Scotland. For example, we know the patient 
was overweight, did not exercise, and consumed a diet relatively high in salt. 
 In terms of factors specific to the underlying membranous nephropathy, her persisting nephrotic 
syndrome will also lead to ongoing salt and fluid retention through activation of the RAS. There are 
also the effects of inflammation and autoimmunity, and all of these factors combine to contribute to 
vascular stiffening, accelerated atherosclerosis, and  therefore worsened hypertension (Table 2). 
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 There were also some excellent suggestions regarding a treatment strategy. What we did in the first 
instance was maximize the ARB, and thereafter attempted to introduce a fourth agent, namely 
amlodipine. Unfortunately, this was not tolerated by the patient, due to worsening of her leg swelling, 
whilst atenolol was contraindicated due to the history of asthma. 
 Consequently, the patient was commenced on the rate-limiting calcium channel antagonist, verapamil. 
However, as can be appreciated from Figure 3, it made little impact on the patient's clinic BP readings, 
which continued to average between 160 and 170 mmHg for systolic BP, and 90 to 100 mmHg for 
diastolic BP. 
 The patient's renal excretory function also started to decline about six months after her initial 
diagnosis, with estimated glomerular filtration rate (eGFR) dropping from around 45 to 25 ml/min/1.73 
m2 over a period of 12 months (Figure 3). Perhaps unsurprisingly, the patient continued to have heavy 
proteinuria, and remained hypoalbuminemic, with an albumin mostly in the range of 15 to 20 g/L. 
 One year following initial presentation, blood results demonstrated a new anemia, most likely as a 
consequence of the declining renal function. Supplementary Table 1 is a summary of the patient's 
investigations at 12 months. Are there any suggestions regarding a management strategy for the 
patient's hypertension at this stage? 
Discussion 
Dr. Zoghby: You mentioned in your earlier slide about the salt intake, which is a very important factor 
here. If a patient is on a high-salt diet, you're not going to accomplish much progress in controlling the 
hypertension without limiting the salt intake. In addition, the patient has severe nephrotic syndrome 
with volume overload, so maybe the diuretic dose is not optimal. If she is volume overloaded, you can 
add six or seven antihypertensives without improvement unless her volume status is controlled. 
Dr. Dhaun: I agree with your comments, and, as I'm sure this audience is aware, reducing salt intake 
per se reduces both BP and proteinuria. I agree that trying to target these general lifestyle factors is 
very important. In terms of the diuretic dose, we are not scared as nephrologists to give doses of 
furosemide up to 500 mg a day. It is usually once the loop diuretic dose is optimized that we consider 
adding in additional classes of diuretics. 
Dr. Mallamaci: Did you say you were sure she was non-dipper? 
Dr. Dhaun: She was a non-dipper. That's right, yes. 
Dr. Mallamaci: What about sleep apnea? 
Dr. Dhaun: That's a good question. I remember this patient well and her physical characteristics 
supported a diagnosis of sleep apnea She snored at night and complained of daytime somnolence but 
had not received an official diagnosis of sleep apnea. 
Dr. Adamczak: The patient’s CKD is still progressing. The first issue is reduction of salt intake. What 
kind of advice was given to the patient? 
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Dr. Dhaun: In the renal clinic, we advise limiting dietary salt intake and suggest ways to do this: salt 
alternatives, not adding salt to cooked food, avoiding foods such as processed meats and white bread 
that contain a lot of salt. Unfortunately, many patients will not adhere to the diets prescribed. 
Dr. Adamczak: It is not enough to say to a patient, "Eat less salt." But it's necessary to advise to avoid 
processed food, which is the most important source of sodium in the diet; 85% of sodium in the diet 
comes from processed food. That is why these instructions should be more complex, not just, “don't 
use salt.” Patients should be advised to reduce processed food intake and replace them with fresh food 
products. This is the first point. Second, the progression of CKD  in this patient is still ongoing. 
Therefore, it's urgently necessary to reduce BP. What can we do? First of all, we can give a calcium 
channel blocker, but maybe another one, lercandipine, which doesn't give peripheral edema. We can 
start the treatment with doxazosin. It would be perfect, especially in this case, in a non-dipper, because 
we can start this treatment with the dose of doxazosin in the evening. It helps to mimic the 
physiological blood pressure dipping pattern. Therefore, my suggestions are: on every visit, discuss salt 
intake, start treatment with doxazosin with small doses, and then escalate the dose and maybe try 
another calcium channel blocker. 
Dr. Dhaun: Those are all excellent suggestions. Doxazosin is a good antihypertensive to choose. As this 
case was from around 20 years ago, the importance of diurnal BP variation and its links to outcome 
were not as well understood as they are now. Additionally, the concept of chronotherapy, that is, 
giving some antihypertensive medications at night, to exaggerate the nocturnal dip in BP in order to 
improve patient outcomes, did not really exist, at least not in renal circles. In terms of reinforcing the 
avoidance of processed food, this was difficult as the patient’s clinic attendance was sporadic. 
Dr. Krekels: Mariella Krekels from The Netherlands. Maybe I missed it because everybody talks very 
fast, but what did happen to her weight when you installed the furosemide? Because I think if she 
didn't lose weight, the first thing I should do is advise the loop diuretic. 
Dr. Dhaun: An excellent point, as weight provides a good measure of fluid balance, provided it is done 
on the same set of scales, at the same time of day, with the same clothing. The patient came to the 
same renal clinic, so weight assessments were probably reliable. Weight was rising, alongside the 
clinical assessment of increasing peripheral edema. This, alongside the declining renal function, 
prompted us to increase the dose of furosemide. You'll see what happens in just a bit. 
Prof. Dominiczak: You’re now giving her lots of drugs. Lots of everything, and you're not having an 
effect. Have we checked the adherence? Because if the patient is not coming to the clinic and takes so 
much salt, despite your advice, I am getting suspicious. That's number one. Secondarily, the six months, 
the magic six months of nephrology have now passed. Is the process in the kidney getting very, very 
severe? Are we now not just idle membranous nephritis, does that become some rapidly progressive 
story? 
Dr. Dhaun: In response to the adherence issue, we did consider this being an issue, reflected by the 
poor clinic attendance, and that weight was increasing with a combination of drugs that work in the 
majority of people. The patient did have one or two admissions to receive intravenous diuretics and, 
during these, with observed dosing, that is, us making sure she was taking her tablets, BP remained 
high. Then, in response to whether we are now reaching the point where the decline in renal function 
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reflects underlying worsening of renal disease, in this case, membranous nephropathy, absolutely, and 
we shall see what happens in a second. 
Dr. Barigou: Concerning the management, my colleagues suggested to increase furosemide. But I think 
that we should add an effective long-acting thiazide diuretic (chlortalidone or indapamide) just to 
optimize nephron blockade at different sites, which would induce a higher natriuretic effect. Moreover, 
I would propose to add a GLP-1 receptor agonist which will have at least four benefits: improving her 
obesity, lowering her blood pressure, improving her renal disease, and decreasing her cardiovascular 
risk (ref : Pi-Sunyer X, Astrup A, et al. N Engl J Med. 2015;373(1):11–22). This would be the ideal 
strategy for me. 
Dr. Dhaun: I think if we were treating this lady now I would agree that management would probably be 
different.  
Dr. Zoghby: I agree with some of the suggestions. However, this patient has been on a lot of 
medications, but we are not addressing the primary underlying process. We know that she has a severe 
nephrotic syndrome, right? She has significant proteinuria. Therefore, by definition, her BP is driven by 
heavy salt intake and volume overload. So really, the first step is to control the volume. The second 
step is controlling the underlying disease (membranous nephropathy). I also failed to mention another 
observation. As a nephrologist, I note that the kidney function declined very quickly and, in the setting 
of severe nephrotic syndrome, one should consider the possibility of renal vein thrombosis 
contributing to her picture as well. 
Dr. Dhaun: Those are all excellent points. The one I'll comment on, in the interest of time, is the last 
one about renal vein thrombosis. At that time, we didn't generally anticoagulate patients with 
membranous nephropathy, which I think we would do now. The clinical picture associated with a renal 
vein thrombosis tends to be an acute decline in renal function, often with a sudden increase in 
peripheral edema. The decline in renal function here was quite gradual. I agree with you about treating 
the underlying disease. It is noteworthy that this case is before the era of screening for antibodies 
against the phospholipase-A2 receptor. 
Dr. Kirpalani: Is it possible that she was taking some other medications? I missed the age, but certainly 
end-stage and contraceptive. 
Dr. Dhaun: She's 41. 
Dr. Kirpalani: Oh no, unlikely. But are there additional medications which she might have been taking?  
Dr. Dhaun: Actually, you make a very good point. She was 41, but there were no hormonal treatments 
that she was taking. Additionally, given the diuretic-resistant edema, one might consider non-steroidal 
anti-inflammatory agents, but there was no suggestion of these. 
Prof. Touyz: Perfect. I think we'll move on in the interest of time. We'll have time in the next little 
series to ask further questions, but let's see how the patient progresses. 
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Case Progression 
First of all, and as has been suggested, we increased the dose of the loop diuretic. That was 
predominately due to issues with persistent peripheral edema. An attempt was also made to introduce 
a fifth antihypertensive agent, an alpha blocker. Unfortunately, the patient failed to tolerate this due to 
headache. As a result, the centrally acting antihypertensive moxonidine was introduced around 12 
months after the diagnosis. 
Additionally, we thought the blood pressure was being driven by the underlying active renal disease. 
As nephrologists, we love to give immunosuppression and so we started the patient on 
immunosuppression during this period. At that time, around 20 years ago, there was no consensus on 
the optimal immunosuppressive regimen for primary membranous nephropathy, meaning the patient 
received numerous different agents during the course of her treatment (Figure 3). Despite the 
immunosuppression, the patient’s excretory function declined further before stabilizing around a GFR-
15, and the patient continued to have nephrotic range proteinuria and an albumin of less than 20. 
Just over two years after her diagnosis, the patient was admitted to hospital with a fluctuating Glasgow 
Coma Scale (GCS) score and brief observed episodes of left-lateral gaze deviation, involuntary eyelid 
twitching, and nystagmus. The patient was markedly hypertensive on admission, with a BP of 225/130 
mmHg. In addition to the antihypertensives listed, the patient was prescribed erythropoietin and oral 
glucocorticoid. 
There were some changes secondary to long-standing hypertension evident in both ECG and 
echocardiogram, although fundoscopy was normal. The patient's computed tomography (CT) and 
magnetic resonance imaging (MRI) brain scans were also normal. Given the patient's presenting 
features and marked hypertension, a diagnosis of hypertensive encephalopathy was considered most 
likely. This diagnosis will not be covered any further during this presentation, as it has been discussed 
previously during a Clinico-Pathologic Conference in 2015 (see weblink). 
Following this admission, we elected to stop all immunosuppression. Our team also reviewed the 
patient's lifestyle and adherence to treatment before commencing the thiazide-like diuretic 
metolazone. Over the subsequent years, the patient's BP remained problematic (Figure 4). The 
patient's admission with hypertensive encephalopathy unfortunately precipitated a significant 
deterioration in the patient's excretory function (Figure 4). She therefore received a pre-emptive renal 
transplant six years after her initial diagnosis. The patient's renal function improved modestly during 
the four years following the transplant. However, her residual function was still relatively poor, with an 
eGFR of around 20 ml/min/1.73 m2. 
She remained hypertensive, and at one year, some further investigations were conducted. The patient 
underwent repeat 24-hour BP measurement and, alongside this, we assessed 24-hour pulse wave 
velocity as a measure of arterial stiffness (Supplementary Table 2). Again, the patient was 
hypertensive, without the expected nocturnal dip in either blood pressure or arterial stiffness. 
Supplementary Table 2 is a summary of the patient's medication at this time, including her 
immunosuppressive regimen at one-year post-transplant. Why do you think the patient's blood 
pressure is proving so difficult to control post-transplant? 
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Discussion  
Prof. Touyz: We have seen for the past 20 years since she first presented, that the BP medication has 
slowly increased in dosage, and we've added a number of new antihypertensive drugs. All of them 
seem to be at maximal or super-maximal concentrations. At what point do you think we should say, 
hang on a minute, how can we rationalize this and actually start removing some of these 
antihypertensive drugs? Because it seems, most likely, that all these extra drugs are probably not doing 
anything beneficial and maybe even some harm. 
Dr. Dhaun: That is a very good point. I suspect we lost focus on the antihypertensives used as we 
probably paid more attention to the immunosuppression we had prescribed and the side effects of 
this. After this, given the patient had received a renal transplant, our focus would have shifted to 
potential immunological problems, such as rejection. I guess we might not have been as on the ball as 
we might have been at managing the hypertension and rationalizing its treatment. 
Dr. Zoghby: I have a couple comments—one comment and one question. My comment: Obviously, it's 
not the case here, but one thing to exclude and discuss with a woman of reproductive age is 
pregnancy, as it can worsen an underlying hypertension or kidney disease. My question: Do we know 
whether her underlying membranous nephropathy is primary or secondary? We assumed it is primary, 
but do you think she could have, for example, lupus with a membranous presentation? 
Dr. Dhaun: Very fair points. 
Dr. Zoghby: And that's something we didn't talk about. Did she have systemic symptoms, such as a rash 
or joint swelling? Did she have any immunologic serology done, such as  double-stranded DNA? Maybe 
you mentioned and I missed it. 
Dr. Dhaun: Again, fair points. The patient was not pregnant, and this was confirmed via testing prior to 
giving any immunosuppression. In terms of your question about whether this could be a secondary 
membranous nephropathy, her renal biopsy showed positive immunofluorescence for IgG4, supporting 
primary membranous nephropathy. Additionally, immunology showed no antibodies against double-
stranded DNA and there was no clinical syndrome in keeping with systemic lupus erythematosus. As 
membranous nephropathy may be secondary to malignancy, some centers may perform CT scanning 
looking for evidence of this; we did not do this in this case as we felt that the histological features and 
the patient’s progression was in keeping with primary membranous nephropathy. 
Dr. Hiremath: Swapnil Hiremath from Ottawa. A couple of comments, which don't address the overall 
course but relate to the fact that she's on tacrolimus and erythropoietin beta. We think the 
hypertension caused by tacrolimus is due to vasoconstriction, which could be antagonized by calcium 
channel blockers, as she's on verapamil but she's not on the dihydropyridine calcium channel blockers 
throughout the course. The second one is that they (calcineurin inhibitors) also act on the thiazide-
sensitive sodium channel, so she's not on a thiazide diuretic—those agents would be helpful.1 The 
second comment, of course, is the role of erythropoietin (EPO) in hypertension. 
Dr. Dhaun: Excellent. As you eloquently describe, one of the contributors to this lady’s hypertension is 
likely to be the tacrolimus. Calcineurin inhibitors cause preferential afferent arteriolar constriction and 
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this may be countermanded by giving a calcium channel blocker that acts primarily to vasodilate the 
arteries. An example would be nifedipine, which is recognized, through the same mechanism, to 
improve eGFR in the post-transplant period. With regards to your comment on tacrolimus activating 
the thiazide-sensitive sodium channels, I hadn't thought of that! Finally, as you say, EPO, especially 
with its chronic use, contributes to hypertension. 
Dr. Adamczak: First, what was the tacrolimus blood concentration? This is crucial, not the tacrolimus 
dose, but blood tacrolimus concentration. Tacrolimus dose should be adjusted to its current blood 
concentration. Tacrolimus blood concentration that is too high leads to calcineurin nephrotoxicity and 
blood pressure increase. Second, it's necessary to check renal artery stenosis of the transplanted 
kidney. The doppler ultrasound of the transplanted kidney renal artery should be done. 
Dr. Dhaun: Thank you. You have made a lot of good points there. First, your question about tacrolimus 
trough levels. The patient had received a well-matched, donation after cardiac death, kidney 
transplant. In this setting, we tend to keep tacrolimus trough levels at 8-10 ng/L in the first six months 
post-transplant. Second, renal artery stenosis in a transplanted kidney is relatively common, but we 
excluded this on the basis of doppler ultrasound, which showed appropriate resistive indices. 
Additionally, this lady was on an ACE inhibitor, and in the setting of significant renal artery stenosis, 
one might expect this to be associated with an unacceptable and progressive decline in renal function. 
Dr. Nademi: I want to know about the inflammatory parameters of this patient. For example,is the 
patient’s C-reactive protein (CRP) concentration elevated? and NA. And also, in these years, does she 
develop something more in other organs like the lung, eye, and others? 
Dr. Dhaun: This patient did have evidence of hypertensive end-organ damage. We described a trans-
thoracic ECHO that demonstrated concentric left ventricular hypertrophy, and her proteinuria might 
well have contributed, in small part, to her hypertension. 
Dr. Nademi: What about lung? Were there any new problems in the lung? 
Dr. Dhaun: In the lung? 
Dr. Nademi: Something like sarcoidosis? 
Dr. Dhaun: No. 
Dr. Nademi: New problem? 
Dr. Dhaun: No. There were no obvious new problems that required us to investigate or image the 
lungs. In terms of the other question about immunology and inflammatory cascade, the problem with 
CRP in these patients is you often will see a low-grade CRP response post-transplant, with levels of 10-
20 mg/L. However, immunology remained negative, and this is about to become relevant! 
Dr. Kirpalani: The general dictum is usually one disease, but did you look at renin and aldosterone 
levels? I mean there might have been primary, which might be hiding in a micro-nodule or something. 
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Dr. Dhaun: That is a very fair point. When she was admitted with hypertensive encephalopathy, she 
underwent CT scanning. That didn't show any obvious macro-nodules. The patient had also had 24-
hour urinary metanephrines done at presentation and these had been normal. 
Case Progress 
So, in addition to the factors contributing to this patient’s hypertension that we have discussed 
previously, we have the immediate effects of immunosuppression, including calcineurin inhibitors, as 
well as the autoimmune response toward the transplanted kidney. There are changes in vascular 
structure and function that predate the transplant. They improved somewhat following transplantation, 
but nevertheless remain significant. Finally, chronic EPO administration is associated with increases in 
arterial BP. This may be related to changes in the production or sensitivity of endogenous 
vasopressors, or as a direct result of basal constrictive effects of EPO itself (Table 2). 
Unfortunately, around four years after she received her transplant, the patient experienced recurrence 
of membranous nephropathy in her graft, confirmed by repeat renal biopsy. This occurs in around one-
third of such patients. Within 24 months, she'd reached end-stage renal failure, and had commenced 
hemodialysis. 
BP remained as much of a problem for this patient, even after commencing hemodialysis, with 
readings averaging around 150 systolic and 90 diastolic (Figure 4). Metolazone was stopped shortly 
after commencing hemodialysis because the patient had started to lose her native urine output. 
For our next discussion point, why does this patient remain hypertensive? And how would you 
manage her hypertension at this stage? 
This woman is now on hemodialysis and in her early 50s. 
Discussion  
Dr. Hiremath: I don't know why she is hypertensive now; I think we have never managed to control her 
hypertension. In hemodialysis, especially given the data, which have  come out recently. There was the 
Italian study a few years ago on carvedilol,2 but then the small Hypertension in Hemodialysis Patients 
Treated with Atenolol or Lisinopril (HDPAL)3 from Dr Agarwal’s group. She's not on a beta blocker. I 
often use beta blockers as first-line or second-line on hemodialysis patients. 
Dr. Dhaun: Absolutely. 
Dr. Hiremath: And there are some observational studies showing that, for end-organ damage, beta 
blockers are perhaps superior to other agents in hemodialysis patients.4,5 
Dr. Dhaun: That is an excellent point. Beta blockers are perhaps the first-line antihypertensive agent in 
dialysis patients, partly because dialysis is arrhythmogenic. In this patient, we had previously tried 
atenolol but had had to stop this as it exacerbated her pre-existing asthma. You could argue we should 
have tried a cardio-specific beta blocker, and that's a fair point. 
Dr. Adamczak: Indeed, during dialysis, the most important cause of the hypertension is overhydration. 
You should intensify fluid removal during dialysis to achieve so-called dry weight. The second important 
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point is sodium concentration in dialysis fluid. What was the current sodium plasma concentration in 
this patient? If sodium plasma concentration in this patient is higher than the sodium concentration in 
dialysis fluid and sodium is transferred to the patient according to concentration gradient, it leads to 
overhydration and to blood pressure increase. Therefore, it is important to make individual decisions 
concerning the sodium concentration in dialysis fluid. The sodium concentration in dialysis fluid should 
be slightly lower than that in the plasma of the patient. 
Dr. Dhaun: Again, very good points. As you say, in dialysis patients, especially in those who have lost 
their native urine output, hypertension is largely dictated by dry weight. That is the fluid weight gain in 
between dialysis sessions. This is managed by asking the patient to limit their fluid intake and maximize 
the tolerated fluid removal on dialysis. As perhaps is evident, this was not the most adherent of 
patients, and trying to restrict fluid, especially when they take a lot of salt in their diet, is challenging. 
Regarding the second thing you pointed out about sodium, we had optimized the technicalities of her 
dialysis through sodium profiling. 
Dr. Naumnik: My question is about what has happened to this graft? Could you perform a kidney 
biopsy? Maybe this patient had a relapse of the membranous nephropathy, or maybe it was a 
rejection? The second question is: what about immunosuppressive therapy? Was it withdrawn 
immediately? 
Dr. Dhaun: That's a very good question. She lost her transplant due to recurrence of membranous 
nephropathy and we performed a biopsy to show that. The biopsy didn't show any evidence of 
rejection. When the patient started hemodialysis, the graft was left in situ. In such patients, we leave 
some immunosuppression in place in order to prevent formation of new antibodies, which might make 
a future transplant difficult. 
Prof. Touyz: Can I ask one question regarding the diuretics that you've used. You've used quite a 
number. I haven't seen any mineralocorticoid receptor blockers, such as spironolactone, and I'm just 
curious, in terms of the accelerated vascular aging and target organ damage. Any thoughts about 
spironolactone? 
Dr. Dhaun: That's an excellent point. In relation to spironolactone, we all appreciate that this is helpful 
for its cardiovascular benefits, especially in those with CKD. The issue in this patient was that we had 
somebody with gradually worsening renal impairment who's already on an ACE inhibitor, and her 
potassium was running at the upper end of what is deemed acceptable. Thus, any episode of acute 
kidney injury might precipitate a hyperkalemic crisis for us; for example, if she took an NSAID for a 
headache, or if she had an episode of volume depletion due to diarrhea. From the diuretic side of 
things, this patient had now lost her urine output by the time she was established on hemodialysis. 
Prof. Dominiczak: A quick additional point. If we assume she took every tablet you ever prescribed, 
and this is an assumption, was there, as our colleagues said before, another condition somewhere? 
Some tubular defect, something very rare, that was reabsorbing sodium that shouldn't be reabsorbed? 
Maybe some syndrome we don't know yet? Help us. 
Dr. Dhaun: I think that's a very fair point. I think the problem in this setting is that you have a known 
underlying glomerular disease (membranous nephropathy), so trying to segregate tubular function, 
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which is affected by glomerular function, is very difficult. Nowadays we might be helped by genetic 
profiling, but this was not widely available to us then. 
In Conclusion 
Excellent suggestions have come from the audience, and certainly an important factor at this stage, 
which we've covered briefly, is dialysis adequacy. The patient was troubled by persistent uremia, 
volume overload, and difficulties in removing fluid during dialysis, all of which will have contributed to 
her high BP readings. There will also be contributory effects from her previous transplant, as well as 
renal vascular changes and disordered bone metabolism, as already highlighted. Finally, two factors 
that have been relevant throughout this patient's journey are her adherence to antihypertensive 
medication and her excessive dietary salt consumption. 
In the first instance, we increased the amount of fluid removed during each dialysis session. We also 
optimized dialysis efficacy through a combination of longer sessions, greater use of biocompatible 
membranes, and a trial of hemodiafiltration to remove more middle-sized molecules. 
 
Summary 
In summary, resistant hypertension is an important diagnosis, especially in patients with CKD, and is a 
problem that is attracting increasing recognition. Indeed, observational studies report a highly variable 
prevalence for resistant hypertension, ranging between 2 and 30%,6 depending partly on how it is 
defined. It is therefore important to consider terminology used in this area. For example, resistant 
hypertension is defined as sub-optimal BP control despite treatment with three or more 
antihypertensive agents of different classes, often including a calcium channel antagonist, an ACE 
inhibitor or ARB, and a diuretic.7 Refractory hypertension is the term used to describe patients whose 
BP remains uncontrolled despite maximal antihypertensive treatment.8 Another important concept is 
that of pseudo-resistant hypertension, which is resistant hypertension caused by something else, such 
as the white-coat effect, other medications, or inaccurate BP measurements.7 
Regardless, resistant hypertension is significantly more common in patients with CKD and in patients 
with cardiovascular disease.9,10 Perhaps unsurprisingly, resistant hypertension is also associated with 
an increased risk of cardiovascular events, with an approximately threefold higher risk of 
cardiovascular events, compared to patients with treated hypertension.11 
Resistant hypertension is also associated with poorer renal outcomes. A sub-analysis of the ALLHAT 
trial demonstrated that progression to end-stage renal disease is almost two-fold higher in patients 
with resistant hypertension compared to normotensive patients.12 
Finally, a word regarding our patient. There was no improvement in her BP over the following years. 
She remained on hemodialysis, but unfortunately suffered a fatal stroke at age 56, just 15 years after 
her initial diagnosis. 
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Figure legends 
Figure 1: Images of the patient’s renal biopsy, from which the patient was diagnosed with 
membranous nephropathy. On the left panel is an image of a glomerulus, with red arrows indicating 
evidence of marked thickening of the glomerular basement membrane. On the right panel is an 
immunofluorescent image of a glomerulus with evidence of granular IgG deposition, which is typical 
for membranous nephropathy. 
 
Figure 2: Graphs of the patient’s clinic blood pressure readings (A), serum creatinine (B), urinary 
protein excretion (C) and serum albumin (D) results during the first 12 months following the patient’s 
initial presentation and diagnosis. 
 
Figure 3: Graph detailing the patient’s clinic blood pressure readings, changes in antihypertensive 
medications and immunosuppressive regimen during the first two years after her initial diagnosis. 
 
Figure 4: Graph illustrating the patient’s clinic blood pressure readings throughout the fourteen years 
following her initial diagnosis, including changes in anti-hypertensive medications during this period. 
Lines with filled circle rather than an arrowhead indicate approximately when that antihypertensive 
medication was stopped
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Table 1. Results of initial investigations. 
 Results Reference Ranges 
Results of initial blood tests 
Creatinine, mg/dL 0.77 (0.67-1.36) 
BUN, mg/dL 8.4 (7.0-18.5) 
Sodium, mmol/L 137 (135-145) 
Potassium, mmol/L 4.2 (3.5-5.0) 
Albumin, g/L 24* (35-50) 
Hemoglobin, g/dL 140 (135-180) 
WCC, ×109/L 10.6 (4.0-11.0) 
Platelets, ×109/L 201 (150-450) 
CRP, mg/L 8* (0-5) 
Cholesterol, mmol/L 6.2*  
Triglycerides, mmol/L  7.4* (0.8-2.1) 
Bilirubin, μmol/L 16 (3-21) 
ALT, IU/L 22 (10-50) 
ALP, IU/L 84 (40-125) 
Autoantibody screen (ANA, ENA screen, PR3, MPO, anti-GBM, anti-CCP) negative  
HBV/HCV/HIV negative  
Early morning serum cortisol, nmol/L 400  
Results of urine tests 
 2 
 
Reference ranges are shown in brackets. Abbreviations: ALT, alanine transferase; ALP, alkaline phosphatase; ABPM, ambulatory blood pressure monitoring; AHA, 
American Heart Association; ANA, anti-nuclear antibodies; BP, blood pressure; BUN, blood urea nitrogen; CRP, C-reactive protein; CCP, anti-cyclic citrullinated 
antibodies; ECG, electrocardiogram; ENA, extractable nuclear antigen antibodies; GBM, glomerular basement membrane antibodies; LVSF, left ventricular systolic 
function; MPO, myeloperoxidase antibodies; PR3, proteinase-3 antibodies; WCC, white cell count; and WHO, World Health Organization. *Indicates value outside the 
reference range. 
 
Protein excretion, g/24h 3.9* (<0.15) 
Sodium excretion, g/24h 3.9* (<2.3 [AHA]/<2.0 [WHO]) 
Salt excretion, g/24h 10* (<6.0 [AHA]/<5.0 [WHO]) 
Cortisol, nmol/24h 146 (20-180) 
Metanephrine, μmol/24h 0.4 (0.3-1.7) 
Normetanephrine, μmol/24h 0.9 (0.4-3.4) 
Results of other tests 
ECG sinus rhythm, no abnormalities 
Echocardiogram normal left ventricular size, good LVSF 
Fundoscopy normal  
24h ABPM 
Systolic BP, mmHg Day 164*  
 Night 160*  
Diastolic BP, mmHg Day 104*  
 Night 98*  
 3 
Table 2. Summary of factors contributing to patient’s hypertension. 
General Factors 
Essential hypertension 
Patient adherence 
Lifestyle 
Salt intake 
Weight 
Physical exertion 
Factors associated with underlying primary membranous nephropathy 
Nephrotic syndrome 
Activation of renin angiotensin system 
Systemic inflammation 
Auto-antibodies: immune-complex mediated endothelial damage 
Endothelin-1 activation 
Factors associated with advanced kidney disease 
Premature arterial ageing and renovascular disease 
Accelerated arteriosclerosis, atherosclerosis and endothelial dysfunction 
Vascular calcification (secondary hyperparathyroidism) 
Increased arterial stiffness, impaired baroreflex sensitivity and autonomic dysfunction 
Erythropoietin administration 
Associated changes in the production or sensitivity of endogenous vasopressors 
Direct vasoconstrictive effect of erythropoietin 
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Adequacy of dialysis 
Persistent uremia, volume overload and inadequate fluid removal 
Factors associated with renal transplantation 
Immunosuppressive medication, e.g. calcineurin inhibitors 
Immunological role of transplanted kidney 
